No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
www.salubris.comNo one on the platform currently holds 002294.SZ.
No tracked institution reports a position in 002294.SZ as of their last filing.
No one on the platform has traded 002294.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 7.2% | 9.3% | 14.8% | — | — | — |
| Rev. Growth % | 7.3% | 9.5% | ||||
| Profit Margin % | 15.1% | 16.6% | 20.4% | |||
| Free Cash Flow Margin % | 3.3% | 11.2% | 18.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $5.3B | +19.8% | $0.76 | $0.76–$0.76 | — | 1 |
| 2027 | $6.4B | +20.3% | $1.00 | $1.00–$1.00 | — | 1 |
| 2028 | $7.5B | +18.0% | $1.20 | $1.20–$1.20 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 6 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-04-20 | $0.18 | $0.06 | -64.7% |
| 2025-10-27 | $0.12 | $0.19 | +61.2% |
| 2025-08-19 | $0.02 | $0.15 | +561.9% |
| 2025-04-21 | $0.18 | $0.18 | +0.0% |
| 2025-03-28 | $0.14 | $0.08 | -42.9% |
| 2024-10-21 | $0.13 | $0.15 | +15.4% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 002294.SZShenzhen Salubris Pharmaceuticals Co., Ltd. | $29.60 | -2.15% | $33.0B | — |
| 000963.SZHuadong Medicine Co., Ltd | $26.19 | -1.02% | $45.9B | — |
| 002001.SZZhejiang NHU Company Ltd. | $26.75 | -0.63% | $82.2B | — |
| 002653.SZHaisco Pharmaceutical Group Co., Ltd. | $63.49 | -0.80% | $71.1B | — |
| 300255.SZHebei Changshan Biochemical Pharmaceutical Co., Ltd. |
| $22.52 |
| -0.40% |
| $20.7B |
| — |
| 300347.SZHangzhou Tigermed Consulting Co., Ltd | $55.81 | -1.05% | $41.2B | — |
| 300896.SZImeik Technology Development Co.,Ltd. | $88.34 | -0.11% | $26.7B | — |
Source: Financial Modeling Prep · peers by sector/industry